Thursday, May 26, 2011 4:08:21 PM
Press Release Source: Cytokinetics, Inc. On Thursday May 26, 2011, 4:00 pm
SOUTH SAN FRANCISCO, CA--(Marketwire - 05/26/11) - Cytokinetics, Incorporated (NASDAQ:CYTK - News) announced today that two posters relating to CK-2017357 are scheduled to be presented at the 22nd Annual Sessions of the Society for Vascular Medicine to be held June 2-4, 2011 at the Seaport Hotel in Boston, MA.
One poster will highlight the results from a Phase IIa Evidence-of-Effect clinical trial evaluating CK-2017357 in patients with claudication associated with peripheral artery disease and the other poster will provide support for the validation of a novel functional endpoint, bilateral heel raise test, in this patient population.
CK-2017357, the lead drug candidate from the company's skeletal muscle contractility program, is a fast skeletal muscle troponin activator and is in Phase IIa clinical trials. CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, leading to an increase in skeletal muscle force. This mechanism of action has demonstrated pharmacological activity in preclinical models that may relate to the potential treatment of diseases associated with aging, muscle wasting or neuromuscular dysfunction.
Poster Presentations at the Society for Vascular Medicine 22nd Annual Scientific Sessions:
Abstract #25: A poster presentation titled "Efficacy and Tolerability Of The Novel Fast Skeletal Muscle Troponin Activator, CK-2017357, In Patients With Claudication" will be on display on Thursday, June 2nd and is scheduled to be presented by Alan Hirsch, MD, Cardiovascular Division and Lillehei Heart Institute, University of Minnesota, from 5:30 PM to 6:30 PM Eastern Time.
Abstract #23: A poster presentation titled "Bilateral Heel Raise Test: A Novel Functional Endpoint For Early Stage Clinical Trials In Peripheral Artery Disease (PAD)," will be on display on Thursday, June 2nd and is scheduled to be presented by Alan Hirsch, MD, Cardiovascular Division and Lillehei Heart Institute, University of Minnesota, from 5:30 PM to 6:30 PM Eastern Time.
http://finance.yahoo.com/news/Cytokinetics-to-Present-iw-4187318011.html?x=0&.v=1
Recent CYTK News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 09:22:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 09:17:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 09:13:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:24:15 PM
- Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants • GlobeNewswire Inc. • 06/17/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/11/2024 09:16:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:22:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 09:08:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:15:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 09:13:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:23:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 02:02:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:30:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:24:59 PM
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/04/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:07:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:36:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:33:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:25:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:20:58 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/03/2024 08:01:38 PM
- Cytokinetics to Participate in June Investor Conferences • GlobeNewswire Inc. • 05/29/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:01:04 PM
- Cytokinetics Announces Closing of Public Offering of Common Stock • GlobeNewswire Inc. • 05/28/2024 08:00:00 PM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM